新发癫痫持续状态的临床谱系
该回顾性队列研究纳入1990年1月1日至2015年12月31日在梅奥诊所(罗切斯特)收治的177例成人新发癫痫持续状态患者,其中惊厥性占70.1%,非惊厥性占29.9%,难治性占54.2%。6个月死亡率为32.2%,平均随访3.1±3.5年时70.1%患者改良Rankin量表评分≥3分(不良功能结局)。年龄≥65岁是不良功能结局和6个月死亡率的显著预测因素。意识丧失、癫痫持续状态分类或年龄≥65岁均不能预测进展为难治性癫痫持续状态。进展为难治性癫痫持续状态未影响末次随访时的功能结局或死亡率。
要点
- 新发癫痫持续状态患者中,惊厥性占70.1%(124/177),非惊厥性占29.9%(53/177),难治性占54.2%(96/177)。
- 6个月死亡率为32.2%,平均随访3.1±3.5年时70.1%患者改良Rankin量表评分≥3分。
- 年龄≥65岁是不良功能结局和6个月死亡率的显著预测因素;本组52.5%患者年龄≥65岁。
- 意识丧失、癫痫持续状态分类或年龄≥65岁均不能预测进展为难治性癫痫持续状态。
- 进展为难治性癫痫持续状态未影响末次随访时的功能结局或死亡率。
适用人群与场景
- 成人新发癫痫持续状态患者,来自1990年1月1日至2015年12月31日于梅奥诊所(罗切斯特)住院的患者。
- 场景:四级学术医疗中心住院患者。
研究设计与关键结果
- 研究类型:回顾性队列;样本量177例;单中心(梅奥诊所,罗切斯特);人群:成人新发癫痫持续状态。
- 癫痫持续状态类型:惊厥性124例(70.1%),非惊厥性53例(29.9%);难治性96例(54.2%)。
- 病因:急性50.8%,进展性18.1%,远期症状性19.2%,未知11.9%。
- 主要结局:6个月死亡率32.2%;平均随访3.1±3.5年时70.1%患者改良Rankin量表评分≥3分(不良功能结局)。
- 年龄≥65岁是不良功能结局和6个月死亡率的显著预测因素。
- 意识丧失、癫痫持续状态分类或年龄≥65岁均不能预测进展为难治性癫痫持续状态。
- 进展为难治性癫痫持续状态未影响末次随访时的功能结局或死亡率。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于新发癫痫持续状态患者,年龄≥65岁提示不良功能结局和6个月死亡风险较高,可用于预后沟通。
- 意识丧失、癫痫持续状态分类或年龄≥65岁不能预测进展为难治性癫痫持续状态。
- 进展为难治性癫痫持续状态未影响末次随访时的功能结局或死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: There is a paucity of data on patients with new-onset status epilepticus in patients without a prior history of epilepsy; we aimed to describe clinical characteristics and assess variables predictive of outcomes.
DESIGN: Retrospective cohort.
SETTING: Quaternary academic medical center.
PATIENTS: Adult patients with new-onset status epilepticus.
METHODS: Retrospective review of adults with new-onset status epilepticus admitted to Mayo Clinic, Rochester MN between January 1, 1990, and December 31, 2015, was performed. Patient demographics, status epilepticus etiology, Status Epilepticus Severity Score, and status epilepticus classification per the Status Epilepticus Severity Score were recorded. Six-month mortality and functional outcomes defined as modified Rankin scale (≥3 at last follow-up was considered poor) were primary outcomes. Refractory status epilepticus was a secondary outcome.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: One-hundred seventy-seven patients were included. Status epilepticus was convulsive in 124 (70.1%) and nonconvulsive in 53 (29.9%); 96 cases (54.2%) were refractory status epilepticus. Mean age at onset was 63 ± 18 years; 52.5% were greater than or equal to 65 years. Etiologies were acute in 50.8%, progressive in 18.1%, remote in 19.2%, and unknown in 11.9% patients. Six-month mortality was 32.2%, and 70.1% had poor modified Rankin scale at mean follow-up 3.1 ± 3.5 years. Age greater than or equal to 65 was a significant predictor of poor functional outcome and 6-month mortality. Loss of consciousness, status epilepticus classification, or age greater than or equal to 65 did not predict progression to refractory status epilepticus. Progression to refractory status epilepticus did not impact functional outcome or mortality at last follow-up.
CONCLUSIONS: Poor outcomes in new-onset status epilepticus were associated with older age as well as predominantly progressive or remote symptomatic disease. Further prospective investigations assessing the course and outcomes of these patients would be useful in management and prognostication.
参考来源
- Chakraborty T, Hocker S. The Clinical Spectrum of New-Onset Status Epilepticus. Crit Care Med. 2019. PMID: 30985452. doi:10.1097/CCM.0000000000003776
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。